

Melanoma Therapeutics: Market Research Report

<https://marketpublishers.com/r/M841DB51219EN.html>

Date: April 2010

Pages: 615

Price: US\$ 3,950.00 (Single User License)

ID: M841DB51219EN

Abstracts

This report analyzes the worldwide markets for Melanoma Therapeutics in US\$ Million.

The report provides separate comprehensive analytics for US, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 73 companies including many key and niche players such as Abraxis BioScience, Inc., Astellas Pharma US, Inc., Antigenics Inc., AVAX Technologies, Inc., BioVex, Inc., GenVec, Inc., GlaxoSmithKline Plc., Medarex Inc., Merck KGAA, Oxford Biomedica Plc, Pfizer, Inc., Progen Pharmaceuticals Limited, and Vical Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.MARKET OVERVIEW

Melanoma Incidence Surging at Significant Rate

Current Standard Treatment for Melanoma

High Unmet Need, and Challenges Abound

Recommencement of Discontinued Trials Provides a Ray a Hope!

Cancer Vaccines: Potentially a Future Aid for Melanoma Treatment

How Does Cancer Vaccines Works?

Whole Cell Vaccines for Melanoma

Melanoma Therapeutics Market: Current & Future Analysis

2.MELANOMA PIPELINE – AN OVERVIEW

Research for Novel Drug Therapies Rampant Worldwide

Selected Products and Targets for Melanoma Treatment Under Phase III Clinical Trials

(As of 2008)

Selected Products and Targets for Melanoma Treatment Under Phase II Clinical Trials

(As of 2008)

Selected Products and Targets for Melanoma Treatment Under Phase I and Pre-Clinical Trials (As of 2008)

Major Drugs Under Investigations for Metastatic Melanoma Treatment (As of 2008)

What Does the Future Hold for Melanoma in Vaccines Space?

Pipeline Analysis of Melanoma Vaccines

Select Companies with Melanoma Vaccines under Phase III Clinical Trials

Select Companies with Melanoma Vaccines under Phase II Clinical Trials

Select Companies with Melanoma Vaccines under Phase I Clinical Trials

3.MELANOMA: THE DISEASE AND TREATMENT

What is Melanoma?

Melanoma of Skin: A Grave form of Skin Cancer

Melanoma Vis-à-vis Other Skin Cancers

Types of Melanoma

Risk Factors for Melanoma

Indoor Tanning Devices Hold Potential for Causing Skin Cancer

Fair Skinned People: At Greater Risk

Prevention of Melanoma

How Is Melanoma Detected?

Ugly Duckling Sign – A New Approach for Melanoma Detection

Diagnosis of Melanoma

Skin Biopsy, an Initial Step

Fine Needle Aspirate (FNA)

Shave Biopsy

Punch Biopsy

Incisional Biopsy

Excisional Biopsy

Process After Biopsy: A Review

Analysis of Lymph Nodes Status, A Second Step

Lactate Dehydrogenase Tests for Metastases Melanoma

Prognosis of the Disease

Melanoma Staging: Crucial for Treatment

Melanoma Treatment: An Overview

Surgical Excision of Melanoma

Sentinel Lymph Node Biopsy

Standard Treatment, Post Surgery

Surgical Adjuvant Treatment

Standard Excision for Lentigo Maligna

Surgical Treatment of Metastatic Melanoma

Stereotactic Radiosurgery For Brain Metastases Melanoma

Chemotherapy for Melanoma

Side Effects

Chemotherapeutic Regional Perfusion

Immunotherapy for Melanoma

Biochemotherapy: Chemo Plus Biotherapy

Radiation Therapy

Vaccine Immunotherapy

Other Treatments

4.RESEARCH FINDINGS

Vitamin D May Prevent Severe Melanoma Lesions

Stress Accelerates Growth Of Melanoma Lesions

Interaction Between Akt3 and (V600E)B-Raf Proteins in a Mole, Leads to Melanoma

5.RESEARCH & DEVELOPMENT

Synta Obtains FDA Approval to Resume Development of Elesclomol

Nexavar Fails in Late Stage Melanoma Trial

Biovex Commences Phase III Clinical Trial of Oncovexgm-CSF

Medarex and Bristol Myers Squibb Announces Enhanced Survival Rate through Ipilimumab

A Pain-Less Melanoma Test, Under Evaluation

Encouraging Phase III Clinical Trials of a Melanoma Vaccine

Plexikon Announces Phase I Results of PLX4032'

Provectus Treats Metastatic Melanoma Patients Under Phase II Clinical Study with PV-10

GENOMEL Project Investigates Environmental/ Genetic Risk Factors for Melanoma

Antigenics Announces Results of a Phase III Trial of Oncophage (vitespen) Vaccine

CuraGen Advances Phase II Clinical Trial of 'CR011-vcMMAE'

Inovio Evaluates a Combination of Plasmid IL-12 and Electroporation Technology for the Treatment of Metastatic Melanoma

6.RECENT INDUSTRY ACTIVITY

Pfizer Collaborates with Debiopharm

PharmaSynth Licenses Muparfostat to Global TransBiotech

Celldex Therapeutics Acquires CuraGen

Bristol-Myers Squibb Acquires Medarex

Cephalon Acquires Outstanding Shares of Arana Therapeutics

ImmunoVaccine Technologies Inks Agreement with Scancell

Vical Inks Agreement with Abic for Allovectin-7 Immunotherapeutic

Immunomedics Collaborates with Alexis Biotech

NeoGenomics Signs Strategic Supply Deal with Abbott

ErgoMed Collaborates with Genzyme

PDS Biotechnology and Merck Eprova Sign CLA

FDA Oncologic Drug Advisory Committee Recommends for Approval, PEGINTRON® for Melanoma Treatment

Takeda Acquires IDM Pharma

Abraxis BioScience Receives FDA's Orphan Drug Status for Abraxane

Progen Pharmaceuticals Spins-Off its Manufacturing Business

Eli Lilly and Company Acquires SGX Pharmaceuticals

GlaxoSmithKline and Synta Pharmaceutical Obtains the Orphan Drug Status from the US FDA, for Elesclomol

Vical Inks Binding LOI with EIP

GammaCan Signs Supply Deal with Bio Products Laboratory

Medarex and Bristol Myers Squibb Delays Submission of BLA, for Ipilimumab

Pfizer Discontinues Phase 3 Clinical Trials of Tremelimumab, in Advanced Melanoma Patients

Alnylam Pharmaceuticals Collaborates with University of California to Evaluate an RNAi Therapeutic for Metastatic Uveal Melanoma Treatment

GenVec and Cobra Ink Manufacturing Agreement

SciClone Pharmaceuticals Signs a Deal with FDA for Thymalfasin

Abraxis BioScience, NCCN, and AstraZeneca Collaborates For Assessment of Abraxane, the Anti-Cancer Drug

Oxford BioMedica Acquires Oxxon Therapeutics

7.FOCUS ON SELECT GLOBAL PLAYERS

Abraxis BioScience, Inc. (USA)

Astellas Pharma US, Inc. (USA)

Antigenics Inc. (USA)

AVAX Technologies, Inc. (USA)

BioVex, Inc. (USA)

GenVec, Inc. (USA)

GlaxoSmithKline Plc. (UK)

Medarex Inc. (USA)

Merck KGAA (Germany)

Oxford Biomedica Plc. (UK)

Pfizer, Inc. (USA)

Progen Pharmaceuticals Limited (Australia)

Vical Inc. (USA)

8.GLOBAL MARKET PERSPECTIVE

Table 1. World Recent Past, Current & Future Analysis for Melanoma Therapeutics Market by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US\$ Million for the Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 2. World Historic Review for Melanoma Therapeutics Market by Geographic Region – US, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US\$ Million for the Years 2001 through 2006 (includes corresponding Graph/Chart)

Table 3. World 15-Year Perspective for Melanoma Therapeutics Market by Geographic Region - Percentage Breakdown of Sales for the US, and Rest of World Markets for the Years 2003, 2009 & 2015

III. MARKET

1. THE UNITED STATES

A. MARKET ANALYSIS

Increasing Incidence of Melanoma Fuels Growth

Table 4. Melanoma Incidence in the US by Gender: 2008

Table 5. Cancer Incidence in Males by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart)

Table 6. Cancer Incidence in Females by Cancer Type: Percentage Share Breakdown in 2008 (includes corresponding Graph/Chart)

Surging Mortality, Demands Novel Therapeutics for Melanoma

Table 7. Melanoma Mortality in the US by Gender: 2005 & 2008 (includes corresponding Graph/Chart)

Table 8. Five-Year Survival Rate for Patients with Melanoma of Skin in the US

(1996-2003): Percentage Share Breakdown by Diagnosis Stage (includes corresponding Graph/Chart)

Fair-Skinned and Light Hair Whites at High Risk

Table 9. Five-Year Survival Rate for Patients with Melanoma of Skin in the US (1996-2003): Percentage Share Breakdown by Race (includes corresponding Graph/Chart)

US Melanoma Fact Sheet: A Recapitulation
Major Players
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 10. US Recent Past, Current & Future Analysis for Melanoma Therapeutics Market with Annual Sales Figures in US\$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)

Table 11. US Historic Review for Melanoma Therapeutics Market with Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)

2.REST OF WORLD

A. MARKET ANALYSIS

Select Regional Markets Under Review

Australia

World's Leading Region with Highest Skin Cancer Incidence

Table 12. Melanoma Incidence Rate in Australia by Age Group: 2008 (2008) (includes corresponding Graph/Chart)

Table 13. Melanoma Incidence Rate in Australian Males by Age Group: 2008 (includes corresponding Graph/Chart)

Table 14. Melanoma Incidence Rate in Australian Females by Age Group: 2008
(includes corresponding Graph/Chart)

Other Key Facts on Melanoma Incidence in Australia

The United Kingdom

Young Women in UK Becoming Increasing Victims of Melanoma

Table 15. Newly Diagnosed Cases of Melanoma of Skin in the UK (2003-2005):
Breakdown by Select Regions, and Gender (includes corresponding Graph/Chart)

Table 16. Mortality Due to Melanoma of Skin in the UK (2003-2005): Breakdown by
Select Regions, and Gender (includes corresponding Graph/Chart)

Major Players

Strategic Corporate Developments

B. MARKET ANALYTICS

Table 17. Rest of World Recent Past, Current & Future Analysis for Melanoma
Therapeutics Market with Annual Sales Figures in US\$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart)

Table 18. Rest of World Historic Analysis for Melanoma Therapeutics Market with
Annual Sales Figures in US\$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 73 (including Divisions/Subsidiaries - 80)

Region/Country Players

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East

I would like to order

Product name: Melanoma Therapeutics: Market Research Report

Product link: <https://marketpublishers.com/r/M841DB51219EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M841DB51219EN.html>